Nanotoxicology in Safety Assessment of Nanomaterials

Since its advent, nanotechnologies are considered key enabling technologies that take advantage of a wide array of nanomaterials (NMs) for biomedical and industrial applications generating significant societal and economic benefits. However, such innovation increases human exposure to these substances through inhalation, ingestion or dermal contact raising public health concerns. Furthermore, the NMs’ specific physicochemical properties, that confer them unique beneficial characteristics, can also elicit nano-bio interactions leading to toxicity and concerns for public health. In addition, such properties can be affected by the surrounding matrix, particularly when incorporated in complex matrices such as food products, leading to secondary features potentially more relevant than primary characteristics for determining their toxicological outcome. These nano specific issues raise the question of whether the NMs may produce adverse outcomes that are not accounted for when usingconventional toxicological approaches to assess their safety.

Such uncertainties about the safety of NMs for human health and the environment may hamper a faster and more widespread exploration of their potentials. In response, the NMs definition has evolved, and nanotoxicology has developed towards new and more integrative approach methods to support regulatory and policy actions.

This book provides a perspective on recent developments in the synthesis, application, and characterization of NMs and the related nanotechnologies, focusing on nanotoxicology for their accurate safety assessment early in the product development stage. The use of complex in vitro models, including multicellular systems and organoids, and “omics-based” approaches, such as transcriptomics or epigenomics, have greatly contributed to an in-depth understanding of the cellular and molecular mechanisms behind some NMs toxicity. Such mechanistic knowledge is equally addressed in this book and has set the basis for a predictive nanotoxicology approach building on adverse outcome pathways. In addition, considering the knowledge provided by the above-mentioned approaches, insights into risk assessment, standardization, and regulation of NMs are also included.

Incorporating adequate nanosafety assessment early in the life-cycle of NMs will allow the implementation of the safe and sustainable-by-design paradigm enabling safety to keep pace with innovation.

Chapters 10 and 15 are available open access under a Creative Commons Attribution 4.0 International License via link.springer.com.

• Nanotechnology
• Safety Assessment
• Predictive toxicology
• Adverse Outcome Pathways
• Nano-bio interactions
• Nanomaterial

• Department of Human Genetics, National Institute of Health Dr. Ricardo Jorge (INSA), Lisbon, Portugal

  Henriqueta Louro

• Department of Human Genetics, National Institute of Health Dr. Ricardo (INSA), Lisbon, Portugal

  Maria João Silva

Henriqueta Louro is a research scientist at the Research and Development Unit of the Department of Human Genetics of the National Institute of Health Dr. Ricardo Jorge (INSA, Lisbon, Portugal) and an integrated member of the Centre for Toxicogenomics and Human Health (ToxOmics, NOVA Medical School, NOVA University of Lisbon). She is graduated in Biochemistry (Faculty of Sciences, Lisbon University) and holds a Ph.D. in Public Health-Environmental and Occupational Health (Nova University of Lisbon). She is a Specialist in Human Genetics (Portuguese Ministry of Health), lecturer at the Toxicology and Health in the Master Course of Human Biology and Environment at the Faculty of Sciences (Lisbon University) and scientific supervisor of M.Sc. and Ph.D. theses. Her main field of research is genetic toxicology and human biomonitoring, with work published in many international peer-reviewed scientific journals, books and communications in international and national congresses. Presently, she participates in the Human Biomonitoring Initiative (HBM4EU) and is the responsible researcher for nationally funded projects on the nanosafety field. Additionally, she is a member of ISO/CEN Portuguese Technical Commission CT194- Nanotechnologies and of the Portuguese consortium for nanosafety, PtOnano.  

Maria João Silva is the principal investigator of the Research Group in Genetic Toxicology at the Department of Human Genetics of the National Institute of Health Dr. Ricardo Jorge (INSA), Lisbon and co-leads the research line on Environmental and Genetic Determinants of Human Disease, Centre for Toxicogenomics and Human Health (ToxOmics), NOVA Medical School, NOVA University of Lisbon). She received her doctoral formation in Genetic Toxicology at INSA after graduation in Pharmaceutical Sciences, holds a specialization in Human Genetics, and is an European Registered Toxicologist. She is also an invited Professor in Master Courses at public and privateUniversities. Her main research interests comprise human and environmental genotoxicity, nanotoxicology, chemicals and mixtures toxicology, and human biomonitoring. She has been involved in several national and European Projects and currently coordinates the HBM4EU Project’s activities at INSA and nationally funded projects on the safety assessment of nanomaterials and nanotechnologies.  She is an expert in the OECD Project 4.095, aimed at the development of the Guidance Document on the adaptation of the "In Vitro micronucleus assay (OECD TG 487) for Testing of Manufactured Nanomaterials”.  

Policies and ethics